{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:48Z","timestamp":1792784928957,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovation center for infectious disease of Jiangsu Province","award":["NO.CXZX202232"],"award-info":[{"award-number":["NO.CXZX202232"]}]},{"name":"Key R&D Program of Jiangsu Province","award":["BE2021603"],"award-info":[{"award-number":["BE2021603"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Influenza viruses pose a persistent threat to global public health, causing widespread respiratory illness and significant morbidity. Vaccination remains the most effective strategy to reduce the burden of both seasonal and pandemic influenza. mRNA vaccines represent a promising alternative to conventional vaccine platforms due to their rapid development, flexibility, and high efficacy. Nonetheless, optimizing non-coding regulatory elements such as untranslated regions (UTRs) remains crucial for enhancing mRNA vaccine performance. In this study, we designed a novel UTR derived from the influenza A virus M segment, engineered to form optimal panhandle structures through selective base-pair enhancing mutations (M1\u2009+\u20092), aiming to improve mRNA translation efficiency and immunogenicity. Using both reporter and HA antigen-encoding mRNAs, we demonstrated that the M1\u2009+\u20092 UTR significantly enhanced protein expression in vitro and in vivo compared to unmodified UTRs and the canonical \u03b1-globin UTR control. In a murine model, low-dose (0.1\u2009\u03bcg) vaccination with HA mRNA-lipid nanoparticles (LNPs) incorporating the M1\u2009+\u20092 UTR elicited robust innate, humoral, and T cell-mediated immune responses, and conferred complete protection against lethal challenge with seasonal influenza strains, including H1N1, H3N2, and IBV. Our findings underscore the potential of rational UTR design in developing more efficacious and dose-sparing mRNA vaccines.<\/jats:p>","DOI":"10.1038\/s41541-026-01463-3","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:15:01Z","timestamp":1777284901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses"],"prefix":"10.1038","volume":"11","author":[{"given":"Yifan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1463_CR1","doi-asserted-by":"publisher","unstructured":"Rotsch, A. H. et al. Mechanism of co-transcriptional cap snatching by influenza polymerase. Nature https:\/\/doi.org\/10.1038\/s41586-026-10189-0 (2026).","DOI":"10.1038\/s41586-026-10189-0"},{"key":"1463_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01339-y","volume":"11","author":"J Hernandez-Davies","year":"2026","unstructured":"Hernandez-Davies, J. et al. Comparative evaluation of 5 combination adjuvants on immunogenicity and efficacy of approved seasonal influenza vaccines. NPJ Vaccines 11, 30 (2026).","journal-title":"NPJ Vaccines"},{"key":"1463_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64829-6","volume":"17","author":"MR Ykema","year":"2026","unstructured":"Ykema, M. R. et al. Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza. Nat. Commun. 17, 434 (2026).","journal-title":"Nat. Commun."},{"key":"1463_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126408","volume":"42","author":"J Taaffe","year":"2024","unstructured":"Taaffe, J. et al. Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact. Vaccine 42, 126408 (2024).","journal-title":"Vaccine"},{"key":"1463_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/vaccines13080863","volume":"13","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Research progress of universal influenza vaccine. Vaccines 13, 863 (2025).","journal-title":"Vaccines"},{"key":"1463_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/v15010116","volume":"15","author":"J Li","year":"2022","unstructured":"Li, J., Zhang, Y., Zhang, X. & Liu, L. Influenza and Universal Vaccine Research in China. Viruses 15, 116 (2022).","journal-title":"Viruses"},{"key":"1463_CR7","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.1021\/acsnano.3c01829","volume":"17","author":"J Pan","year":"2023","unstructured":"Pan, J. et al. An intranasal multivalent epitope-based nanoparticle vaccine confers broad protection against divergent influenza viruses. ACS Nano 17, 13474\u201313487 (2023).","journal-title":"ACS Nano"},{"key":"1463_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2494702","volume":"14","author":"J Mao","year":"2025","unstructured":"Mao, J. et al. Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection. Emerg. Microbes Infects 14, 2494702 (2025).","journal-title":"Emerg. Microbes Infects"},{"key":"1463_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127165","volume":"56","author":"MNN Fatimah","year":"2025","unstructured":"Fatimah, M. N. N. et al. Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections. Vaccine 56, 127165 (2025).","journal-title":"Vaccine"},{"key":"1463_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu7646","volume":"17","author":"C Jacob-Dolan","year":"2025","unstructured":"Jacob-Dolan, C. et al. Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Sci. Transl. Med. 17, eadu7646 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1463_CR11","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1016\/j.vaccine.2022.06.078","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects \u22653 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial. Vaccine 40, 4933\u20134941 (2022).","journal-title":"Vaccine"},{"key":"1463_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/bit.28925","volume":"122","author":"R Correia","year":"2025","unstructured":"Correia, R. et al. Continuous Production of Influenza VLPs Using IC-BEVS and Multi-Stage Bioreactors. Biotechnol. Bioeng. 122, 846\u2013857 (2025).","journal-title":"Biotechnol. Bioeng."},{"key":"1463_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target Ther. 8, 149 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1463_CR14","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3389\/fimmu.2018.01568","volume":"9","author":"LYY Lee","year":"2018","unstructured":"Lee, L. Y. Y., Izzard, L. & Hurt, A. C. A review of DNA vaccines against influenza. Front Immunol. 9, 1568 (2018).","journal-title":"Front Immunol."},{"key":"1463_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1126\/science.adw3278","volume":"387","author":"JL Goodman","year":"2025","unstructured":"Goodman, J. L. et al. Prepare now for a potential H5N1 pandemic. Science 387, 1047 (2025).","journal-title":"Science"},{"key":"1463_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","volume":"625","author":"TE Mulroney","year":"2024","unstructured":"Mulroney, T. E. et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature 625, 189\u2013194 (2024).","journal-title":"Nature"},{"key":"1463_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 10, 594 (2019).","journal-title":"Front Immunol."},{"key":"1463_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","volume":"601","author":"M Gebre","year":"2022","unstructured":"Gebre, M. et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature 601, 410\u2013414 (2022).","journal-title":"Nature"},{"key":"1463_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403 (2023).","journal-title":"Nature"},{"key":"1463_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","volume":"42","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. 42, 194\u2013203 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1463_CR21","doi-asserted-by":"publisher","first-page":"8303","DOI":"10.1128\/JVI.79.13.8303-8315.2005","volume":"79","author":"WW Chiu","year":"2005","unstructured":"Chiu, W. W., Kinney, R. M. & Dreher, T. W. Control of translation by the 5\u2019- and 3\u2019-terminal regions of the dengue virus genome. J. Virol. 79, 8303\u20138315 (2005).","journal-title":"J. Virol."},{"key":"1463_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1252","volume":"53","author":"M Wolczyk","year":"2025","unstructured":"Wolczyk, M. et al. 5\u2019 terminal nucleotide determines the immunogenicity of IVT RNAs. Nucleic Acids Res. 53, gkae1252 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1463_CR23","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1128\/JVI.00232-15","volume":"89","author":"G Liu","year":"2015","unstructured":"Liu, G., Park, H. S., Pyo, H. M., Liu, Q. & Zhou, Y. Influenza A virus panhandle structure is directly involved in RIG-I activation and interferon induction. J. Virol. 89, 6067\u20136079 (2015).","journal-title":"J. Virol."},{"key":"1463_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tim.2010.12.002","volume":"19","author":"SM McDonald","year":"2011","unstructured":"McDonald, S. M. & Patton, J. T. Assortment and packaging of the segmented rotavirus genome. Trends Microbiol. 19, 136\u2013144 (2011).","journal-title":"Trends Microbiol."},{"key":"1463_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1073\/pnas.1013155108","volume":"108","author":"K Terasaki","year":"2011","unstructured":"Terasaki, K., Murakami, S., Lokugamage, K. G. & Makino, S. Mechanism of tripartite RNA genome packaging in Rift Valley fever virus. Proc. Natl. Acad. Sci. USA 108, 804\u2013809 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1463_CR26","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1073\/pnas.84.22.8140","volume":"84","author":"MT Hsu","year":"1987","unstructured":"Hsu, M. T., Parvin, J. D., Gupta, S., Krystal, M. & Palese, P. Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. Proc. Natl. Acad. Sci. USA 84, 8140\u20138144 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1463_CR27","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1128\/jvi.68.6.4092-4096.1994","volume":"68","author":"E Fodor","year":"1994","unstructured":"Fodor, E., Pritlove, D. C. & Brownlee, G. G. The influenza virus panhandle is involved in the initiation of transcription. J. Virol. 68, 4092\u20134096 (1994).","journal-title":"J. Virol."},{"key":"1463_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).","journal-title":"Nat. Commun."},{"key":"1463_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41577-021-00608-w","volume":"21","author":"K Karik\u00f3","year":"2021","unstructured":"Karik\u00f3, K. Modified uridines are the key to a successful message. Nat. Rev. Immunol. 21, 619 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1463_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"1463_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214320120","volume":"120","author":"T Tockary","year":"2023","unstructured":"Tockary, T. et al. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc. Natl. Acad. Sci. USA 120, e2214320120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1463_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345\u2013351 (2015).","journal-title":"J. Control Release"},{"key":"1463_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00900-5","volume":"9","author":"K Lemdani","year":"2024","unstructured":"Lemdani, K. et al. Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging. NPJ Vaccines 9, 113 (2024).","journal-title":"NPJ Vaccines"},{"key":"1463_CR34","doi-asserted-by":"publisher","first-page":"16151","DOI":"10.1021\/acsnano.4c01171","volume":"18","author":"A Hamilton","year":"2024","unstructured":"Hamilton, A. et al. High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route. ACS Nano 18, 16151\u201316165 (2024).","journal-title":"ACS Nano"},{"key":"1463_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","volume":"39","author":"J Di","year":"2022","unstructured":"Di, J. et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm. Res. 39, 105\u2013114 (2022).","journal-title":"Pharm. Res."},{"key":"1463_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","volume":"3","author":"KE Lindsay","year":"2019","unstructured":"Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371\u2013380 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"1463_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nri1669","volume":"5","author":"RE Mebius","year":"2005","unstructured":"Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat. Rev. Immunol. 5, 606\u2013616 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"1463_CR38","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"P Sample","year":"2019","unstructured":"Sample, P. et al. Human 5\u2019 UTR design and variant effect prediction from a massively parallel translation assay. Nat. Biotechnol. 37, 803\u2013809 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1463_CR39","doi-asserted-by":"publisher","first-page":"24075","DOI":"10.1073\/pnas.1908052116","volume":"116","author":"DM Mauger","year":"2019","unstructured":"Mauger, D. M. et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl. Acad. Sci. USA 116, 24075\u201324083 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1463_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/d41586-021-01661-0","volume":"594","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. CureVac COVID vaccine let-down spotlights mRNA design challenges. Nature 594, 483 (2021).","journal-title":"Nature"},{"key":"1463_CR41","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.3390\/ijms23158285","volume":"23","author":"W Li","year":"2022","unstructured":"Li, W., Wang, H. & Zheng, S. Roles of RNA Sensors in Host Innate Response to Influenza Virus and Coronavirus Infections. Int. J. Mol. Sci. 23, 8285 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1463_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim, S. et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat. Commun. 15, 7226 (2024).","journal-title":"Nat. Commun."},{"key":"1463_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez, S., Lacroix, C., Exposito, J. Y. & Verrier, B. Tailoring mRNA Vaccine to Balance Innate\/Adaptive Immune Response. Trends Mol. Med. 26, 311\u2013323 (2020).","journal-title":"Trends Mol. Med."},{"key":"1463_CR44","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","volume":"38","author":"BR Anderson","year":"2010","unstructured":"Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884\u20135892 (2010).","journal-title":"Nucleic Acids Res."},{"key":"1463_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","volume":"18","author":"X Han","year":"2023","unstructured":"Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105\u20131114 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"1463_CR46","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1126\/science.adc9449","volume":"376","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. Better lipids to power next generation of mRNA vaccines. Science 376, 680\u2013681 (2022).","journal-title":"Science"},{"key":"1463_CR47","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1463_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00838-8","volume":"9","author":"L Marcos-Villar","year":"2024","unstructured":"Marcos-Villar, L. et al. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium. NPJ Vaccines 9, 53 (2024).","journal-title":"NPJ Vaccines"},{"key":"1463_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"1463_CR50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cell.2025.01.019","volume":"188","author":"H Song","year":"2025","unstructured":"Song, H. et al. Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin. Cell 188, 919\u2013929.e919 (2025).","journal-title":"Cell"},{"key":"1463_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404365","volume":"11","author":"A Ouyang","year":"2024","unstructured":"Ouyang, A. et al. The hemagglutinin of influenza A virus induces ferroptosis to facilitate viral replication. Adv. Sci. 11, e2404365 (2024).","journal-title":"Adv. Sci."},{"key":"1463_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00980-3","volume":"9","author":"T Hauguel","year":"2024","unstructured":"Hauguel, T. et al. Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines. NPJ Vaccines 9, 183 (2024).","journal-title":"NPJ Vaccines"},{"key":"1463_CR53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"1463_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"1463_CR55","doi-asserted-by":"publisher","first-page":"e02299","DOI":"10.1128\/JVI.02299-18","volume":"93","author":"G Liu","year":"2019","unstructured":"Liu, G. & Zhou, Y. Cytoplasm and beyond: dynamic innate immune sensing of influenza A virus by RIG-I. J. Virol. 93, e02299\u201318 (2019).","journal-title":"J. Virol."},{"key":"1463_CR56","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2010.01.020","volume":"140","author":"J Rehwinkel","year":"2010","unstructured":"Rehwinkel, J. et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140, 397\u2013408 (2010).","journal-title":"Cell"},{"key":"1463_CR57","doi-asserted-by":"publisher","first-page":"e1005754","DOI":"10.1371\/journal.ppat.1005754","volume":"12","author":"M Kandasamy","year":"2016","unstructured":"Kandasamy, M. et al. RIG-I signaling is critical for efficient polyfunctional T cell responses during influenza virus infection. PLoS Pathog. 12, e1005754 (2016).","journal-title":"PLoS Pathog."},{"key":"1463_CR58","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1463_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"L Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1463_CR60","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","volume":"43","author":"JD Burke","year":"2019","unstructured":"Burke, J. D. & Young, H. A. IFN-\u03b3: A cytokine at the right time, is in the right place. Semin. Immunol. 43, 101280 (2019).","journal-title":"Semin. Immunol."},{"key":"1463_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"1463_CR62","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou, C., Gao, Y., Ding, P., Wu, T. & Ji, G. The role of CXCL family members in different diseases. Cell Death Discov. 9, 212 (2023).","journal-title":"Cell Death Discov."},{"key":"1463_CR63","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272\u2013280 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1463_CR64","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li, L. et al. HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells. Cancer Immunol. Res. 11, 657\u2013673 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"1463_CR65","doi-asserted-by":"publisher","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","volume":"101","author":"S Singh","year":"2021","unstructured":"Singh, S., Anshita, D. & Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 101, 107598 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1463_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","volume":"40","author":"T Kishimoto","year":"2022","unstructured":"Kishimoto, T. & Kang, S. IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu. Rev. Immunol. 40, 323\u2013348 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"1463_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","volume":"29","author":"W Ouyang","year":"2011","unstructured":"Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71\u2013109 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"1463_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target Ther. 7, 94 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1463_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 8, 156 (2023).","journal-title":"NPJ Vaccines"},{"key":"1463_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70792-x","volume":"14","author":"Q Ma","year":"2024","unstructured":"Ma, Q. et al. Optimization of the 5\u2019 untranslated region of mRNA vaccines. Sci. Rep. 14, 19845 (2024).","journal-title":"Sci. Rep."},{"key":"1463_CR71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtcme.2024.03.008","volume":"15","author":"H Wei","year":"2024","unstructured":"Wei, H. et al. Network pharmacology-based study to investigate the mechanism of compound houttuynia mixture against influenza virus infection by suppressing TLR7\/MyD88 signaling pathway. J. Tradit. Complement. Med. 15, 237\u2013249 (2024).","journal-title":"J. Tradit. Complement. Med."},{"key":"1463_CR72","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","volume":"94","author":"RW Herzog","year":"1997","unstructured":"Herzog, R. W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 5804\u20135809 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1463_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02123572","volume":"162","author":"K Tobita","year":"1975","unstructured":"Tobita, K., Sugiura, A., Enomote, C. & Furuyama, M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162, 9\u201314 (1975).","journal-title":"Med. Microbiol. Immunol."},{"key":"1463_CR74","doi-asserted-by":"publisher","first-page":"e26175","DOI":"10.1371\/journal.pone.0026175","volume":"6","author":"J Tu","year":"2011","unstructured":"Tu, J. et al. Effects of the C-terminal truncation in NS1 protein of the 2009 pandemic H1N1 influenza virus on host gene expression. PLoS One 6, e26175 (2011).","journal-title":"PLoS One"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01463-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:10:41Z","timestamp":1782954641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01463-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01463-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}